✦ LIBER ✦

NM 283 has potent antiviral activity against genotype 1 chronic hepatitis C virus (HCV-1) infection in the chimpanzee

✍ Scribed by D.N. Standring; R. Lanford; T. Wright; R.T. Chung; V. Bichko; E. Cretton-Scott; X. Pan-Zhou; S. Bergelson; L. Qu; M. Tausek; E. Bridges; A. Moussa; R. Storer; C. Pierra; S. Benzaria; G. Gosselin; P. La Colla; J.P. Sommadossi

Book ID: 117372343
Publisher: Elsevier Science
Year: 2003
Tongue: English
Weight: 145 KB
Volume: 38
Category: Article
ISSN: 0168-8278
DOI: 10.1016/s0168-8278(03)80421-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Antiviral activity of the hepatitis C vi

Antiviral activity of the hepatitis C virus polymerase inhibitor filibuvir in genotype 1–infected patients

✍ Frank Wagner; Robert Thompson; Constantino Kantaridis; Paul Simpson; Philip J. F 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 599 KB

More effective and better-tolerated therapies are needed for chronic hepatitis C virus (HCV) infection. Among the direct-acting anti-HCV agents in development is the nonstructural 5B protein (NS5B polymerase) non-nucleoside inhibitor filibuvir. We investigated the antiviral activity, pharmacokinetic

93 Enhanced antiviral efficacy for valop

93 Enhanced antiviral efficacy for valopicitabine (NM283) plus peg-interferon in hepatitis C patients with HCV genotype-1 infection: Results of a phase IIa multicenter trial

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 234 KB

963 SAFETY AND A ANTIVIRAL ACTIVITY OF A

963 SAFETY AND A ANTIVIRAL ACTIVITY OF A MONOTHERAPY WITH A MP-424 FOR 24 WEEKS IN NAIVE PATIENTS WITH CHRONIC HEPATITIS C VIRUS GENOTYPE 1B INFECTION

✍ I. Ozeki 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 47 KB

OL-006 Impact of mutation in HCV ISDR on

OL-006 Impact of mutation in HCV ISDR on the efficacy of the combined pegylated interferon/ribavirin therapy in Chinese patients with chronic hepatitis C virus genotype 1b infection

✍ J.T. Li; J.F. Wei; Y.P. Zhou; W. Li; Y.L. Zeng; J.J. Wang; B. Zhou; S.W. Liu; Y. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 51 KB

PGI2 IS THERE ANY DIFFERENCE BETWEEN THE

PGI2 IS THERE ANY DIFFERENCE BETWEEN THE EFFECTS OF THERAPY WITH PEGINTERFERON-ALPHA-2A VERSUS STANDARD-DOSE PEGINTERFERON-ALPHA-2B? A META-ANALYSIS COMPARING BOTH TREATMENTS PLUS RIBAVIRIN IN GENOTYPE 1/4 CHRONIC HEPATITIS C VIRUS (HCV) INFECTION PATIENTS

✍ FMR Barros; H Cheinquer; LG Borges; E Santos 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 75 KB